Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.

JCO precision oncology - 1 Jun 2026

Peshin Supriya, Saj Fen, Kasi Pashtoon M, David Felicity, Szklaruk Janio, Kimana Quentin, Pant Shubham, Lee Sunyoung S, Knox Jennifer J, Borad Mitesh J, Javle Milind

Abstract excerpt

PURPOSE: EGFR alterations occur in a subset of biliary tract cancers (BTCs) and are often linked to disease progression and poor prognosis, yet targeted approaches remain underexplored. ERRFI1, encoding the epidermal growth factor receptor (EGFR) inhibitor MIG6, is mutated in various cancers, including BTC, representing a potential predictive biomarker. We investigated whether loss of ERRFI1 function may enhance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biliary Tract Neoplasms

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42234947
DOI: 10.1200/PO-25-00673
PMCID: PMC13252979

Genes

EGFR
ERRFI1
BTC
ARID1A
IDH1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.PMID 42234947Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Molecular profiling of biliary tract cancer: a target rich diseaseSemantic proximity Read ↗

Targeted therapies in advanced biliary malignancies: a clinical review.Semantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment OptionsSemantic proximity Read ↗

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.Semantic proximity Read ↗

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug TargetsSemantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Semantic proximity Read ↗

Genomic spectra of biliary tract cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.